116 related articles for article (PubMed ID: 31292985)
1. Pharmacokinetic modeling of the blood-stable camptothecin analog AR-67 in two different formulations.
Liu X; Adane E; Tang F; Leggas M
Biopharm Drug Dispos; 2019 Sep; 40(8):265-275. PubMed ID: 31292985
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors.
Tang F; Tsakalozou E; Arnold SM; Ng CM; Leggas M
Invest New Drugs; 2019 Dec; 37(6):1218-1230. PubMed ID: 30820810
[TBL] [Abstract][Full Text] [Related]
3. Cremophor EL Alters the Plasma Protein Binding and Pharmacokinetic Profile of Valspodar in Rats.
Binkhathlan Z
Drug Res (Stuttg); 2017 Oct; 67(10):591-595. PubMed ID: 28628923
[TBL] [Abstract][Full Text] [Related]
4. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicological studies of cremophor EL free alternative paclitaxel formulation.
Utreja P; Jain S; Yadav S; Khandhuja KL; Tiwary AK
Curr Drug Saf; 2011 Nov; 6(5):329-38. PubMed ID: 22424541
[TBL] [Abstract][Full Text] [Related]
6. Probing a potential in vivo drug-excipient interaction: temporal effects of a modified β-cyclodextrin on the intravenous pharmacokinetics of a model high-affinity drug ligand.
Mannila A; Morizzi J; Nguyen TT; Charman SA; McIntosh MP; Shackleford DM
J Pharm Sci; 2012 Sep; 101(9):3381-9. PubMed ID: 22549698
[TBL] [Abstract][Full Text] [Related]
7. Alphaxalone Reformulated: A Water-Soluble Intravenous Anesthetic Preparation in Sulfobutyl-Ether-β-Cyclodextrin.
Goodchild CS; Serrao JM; Kolosov A; Boyd BJ
Anesth Analg; 2015 May; 120(5):1025-1031. PubMed ID: 25517195
[TBL] [Abstract][Full Text] [Related]
8. Use of solubilizers in preclinical formulations: Effect of Cremophor EL on the pharmacokinetic properties on early discovery compounds.
Liu B; Gordon WP; Richmond W; Groessl T; Tuntland T
Eur J Pharm Sci; 2016 May; 87():52-7. PubMed ID: 26499309
[TBL] [Abstract][Full Text] [Related]
9. Drug product development and pharmacological evaluation of a sparingly soluble novel camptothecin analog for peroral administration.
Nekkanti V; Karatgi P; Paruchuri S; Pillai R
Drug Deliv; 2011 May; 18(4):294-303. PubMed ID: 21214430
[TBL] [Abstract][Full Text] [Related]
10. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.
Tsakalozou E; Adane ED; Liang Y; Arnold SM; Leggas M
Cancer Chemother Pharmacol; 2014 Jul; 74(1):45-54. PubMed ID: 24807458
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation.
Jain SK; Utreja P; Tiwary AK; Mahajan M; Kumar N; Roy P
Curr Drug Saf; 2014; 9(2):145-55. PubMed ID: 24369111
[TBL] [Abstract][Full Text] [Related]
12. New injectable melphalan formulations utilizing (SBE)(7m)-beta-CD or HP-beta-CD.
Ma DQ; Rajewski RA; Stella VJ
Int J Pharm; 1999 Nov; 189(2):227-34. PubMed ID: 10536251
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of a sulfobutyl ether beta-cyclodextrin enabled etomidate formulation.
McIntosh MP; Schwarting N; Rajewski RA
J Pharm Sci; 2004 Oct; 93(10):2585-94. PubMed ID: 15349968
[TBL] [Abstract][Full Text] [Related]
14. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.
Adane ED; Liu Z; Xiang TX; Anderson BD; Leggas M
Pharm Res; 2012 Jul; 29(7):1722-36. PubMed ID: 22068278
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles.
Dhanikula AB; Singh DR; Panchagnula R
Curr Drug Deliv; 2005 Jan; 2(1):35-44. PubMed ID: 16305406
[TBL] [Abstract][Full Text] [Related]
17. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
18. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
19. Cyclodextrin nanoparticle bound oral camptothecin for colorectal cancer: Formulation development and optimization.
Ünal S; Aktaş Y; Benito JM; Bilensoy E
Int J Pharm; 2020 Jun; 584():119468. PubMed ID: 32470483
[TBL] [Abstract][Full Text] [Related]
20. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
